SCHEMBL2037071

SCHEMBL2037071

C[C@@H](Oc1cc(Cl)ccc1Cl)c1ccnc(N)n1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.81
HTR2A P28223 6/20 0.48
HTR7 P34969 6/20 0.48
HTR6 P50406 6/20 0.48
DRD2 P14416 5/20 0.48
NOS2 P35228 1/20 0.41
DHFR P00374 2/20 0.39
MAPK1 P28482 1/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
GAA P10253 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAP3K14 Q99558 2/20 0.39
HTR1A P08908 3/20 0.39
KMO O15229 1/20 0.38
MET P08581 1/20 0.38
ROCK1 Q13464 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2037073 1.00 POLB (0.81) POLBHTR2AHTR7HTR6DRD2
SCHEMBL2033241 0.89 POLB (1.00) POLBHTR2AHTR7HTR6DRD2
SCHEMBL13277831 0.88 POLB (0.70) POLBHTR2AHTR7HTR6DRD2
SCHEMBL13277833 0.88 POLB (0.70) POLBHTR2AHTR7HTR6DRD2
SCHEMBL2031705 0.87 POLB (0.65) POLBHTR2AHTR7HTR6DRD2
SCHEMBL2031702 0.87 POLB (0.65) POLBHTR2AHTR7HTR6DRD2
SCHEMBL2037516 0.84 POLB (0.61) POLBHTR2AHTR7HTR6DRD2
SCHEMBL2037517 0.84 POLB (0.61) POLBHTR2AHTR7HTR6DRD2
SCHEMBL2035787 0.83 POLB (0.71) POLBHTR2AHTR7HTR6DRD2
SCHEMBL2035785 0.83 POLB (0.71) POLBHTR2AHTR7HTR6DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516397-B1 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME (NL) 2016-07-13 EP disclosed
US-8952001-B2 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME CORP. (US) 2015-02-10 US disclosed
CN-102884048-B Amino-heteroaryl derivatives as HCN blockers MSD OSS BV 2014-07-23 CN disclosed
CN-102884048-A Amino-heteroaryl derivatives as HCN blockers MSD OSS BV 2013-01-16 CN disclosed
EP-2516397-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS MSD Oss B.V. (NL) 2012-10-31 EP disclosed
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-10-18 US disclosed
WO-2011076723-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS N.V. ORGANON (NL) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS HCN1, HCN3, HCN2 POLB 3931/4885HTR2A 272/4885HTR7 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.